LatestLow-Dose Naltrexone: A Small Dose, A Large Set of Claims
A fifty-year-old opioid blocker, prescribed at a tenth of its approved dose for fibromyalgia, long COVID, ME/CFS and MS. The mechanistic story is elegant, the trial record is messier — and 2026 delivered an uncomfortable correction to the field’s most-cited positive number.
Revuelt Health · October 20, 2026 · 10 min read
Read


